LETTER TO THE EDITOR

Bariatric Surgeries and COVID-19 Outcomes: More and More Benefits

Ahmad A. Toubasi

Received: 30 May 2021 / Revised: 11 June 2021 / Accepted: 17 June 2021 / Published online: 7 July 2021

The rising prevalence of obesity has led to an increase in the evolution of bariatric surgeries. Several studies showed the superiority of bariatric surgeries compared to medical therapy in weight loss. In addition to its huge efficacy in weight loss, bariatric surgeries ameliorate several obesity-related complications like diabetes, hypertension, and dyslipidemia. Furthermore, several studies showed that bariatric surgeries were associated with a significant reduction in mortality [1]. The COVID-19 pandemic caused millions of deaths worldwide resulting in a public health emergency. In the absence of effective treatment, several risk and protective factors have been established to decrease the mortality of this disease. One of the contributing factors of COVID-19 severity is obesity as observational studies revealed that obese patients were more likely to die due to COVID-19 [2]. In addition, obesity can lead to several comorbidities like diabetes, cardiovascular diseases, and tumors, and all of them are considered risk factors for COVID-19 severity and mortality [3].

The following databases, PubMed, ScienceDirect, Google Scholar, and medRxiv, were searched up to 23 May 2021 using COVID-19 and Bariatric surgery and their related MeSH terms. Studies were included if they were cohort or case control in design, included COVID-19 patients, compared between bariatric surgeries patients and control group in terms of COVID-19 severity and mortality, and adjusted for confounding variables. The exposure of interest was bariatric surgery regardless of the type of surgery and the outcome of interest was COVID-19 severity and mortality. COVID-19 mortality was defined as death and COVID-19 severity was defined as mechanical ventilation and intensive care unit (ICU) admission. The search results were screened using title and abstract then the remaining articles were tested against the inclusion criteria using its full-text form. The quality of the included studies was assessed using the Newcastle-Ottawa Scale for observational studies (NOS). The adjusted odds ratio (OR) and its related 95% confidence interval (95%CI) were pooled using the random effect model using Meta XL, version 5.3 (EpiGear International, Queensland, Australia). Cochran’s Q heterogeneity test and I2 statistic were performed to estimate the heterogeneity.

The search yielded 1599 articles; after deduplication and applying the inclusion criteria, 3 articles [4–6] were included in the analysis (Fig. 1). The total number of COVID-19 patients included in the included articles was 9269. Of them, 13.3% (698/9269) underwent bariatric surgery and the rest were controls. The quality of all of the included studies was good (9/9). Furthermore, 8.5% (58/698) of bariatric surgery patients developed severe COVID-19 infection and 3.9% (27/698) of them died. In comparison, 16.1% of controls developed severe COVID-19 infection (1382/8571) and 13.7% (1174/8571) of them died. The characteristics of the included studies are described in Table 1. The analysis showed that bariatric surgery was significantly associated with reduced risk of COVID-19 severity (Fig. 2; OR = 0.46; 95%CI: 0.24–0.88) and the heterogeneity of this model was significant (I2 = 67%; P-value = 0.05). Moreover, bariatric surgery was significantly associated with a reduced risk of COVID-19 mortality (Fig. 3; OR=0.50; 95%CI: 0.33–0.76) and the heterogeneity of this model was insignificant (I2 = 0%; P-value = 1.00).

Our analysis revealed that patients with a history of bariatric surgeries had a significant reduction by 54% in the risk of ICU admission and mechanical ventilation due to COVID-19. This result was similar across the included studies as all of
Table 1  The characteristics of the included studies

| Study           | Country | Study design       | Number of participants | Age for the control group (median/mean ± STDV) | Age for the bariatric surgery group (median/mean ± STDV) | BMI for the control group | BMI for the bariatric surgery group | Number of patients who developed severe COVID-19 infection in the control group (%) | Number of patients who developed severe COVID-19 infection in the bariatric surgery group (%) | Number of patients who died due to COVID-19 infection in the control group (%) | Number of patients who died due to COVID-19 infection in the bariatric surgery group (%) | Adjusted confounding variables | Score |
|-----------------|---------|--------------------|-------------------------|------------------------------------------------|--------------------------------------------------------|--------------------------|------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|----------|
| Amenian et al.  | USA     | Retrospective cohort | 363                     | 49.8 ± 14.3            | 46.1 ± 12.7                                           | 46.7 ± 6.4               | 37.2 ± 7.1                       | 65/330 (19.7)                                                                 | 0/33 OR = 0.06 (0.00–1.00)                                                                 | 8/330 (2.4)                                                                                                                       | 0/33 OR = 0.57 (0.03–10.03)                                                                 | BMI, sex, age, race, ethnicity, smoking status, history of hypertension, diabetes, coronary artery disease, heart failure, asthma, COPD, cancer, and use of a steroid, angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker | 9        |
| Jenkins et al.  | USA     | Retrospective cohort | 620                     | 52.1 ± 12.9            | 51.7 ± 12.6                                           | 41.4 ± 6.5               | 36.1 ± 8.3                       | 159/496 (32.1)                                                                 | 20/124 (16.1) OR = 0.41; 95%CI: 0.24–0.68 68/496 (13.7)                                                                 | 8/124 (6.5) OR = 0.51; 95%CI: 0.22–1.17 19/541 (3.5) OR = 0.50; 95%CI: 0.31–0.80 |                                                                                              |                                                                                                                                                                                                 | 9        |
| Iannelli et al. | France  | Retrospective cohort | 8286                    | 59.8 (12.4)           | 49.8 (12.0)                                           | -                       | -                                 | 1158/7745 (15)                                                                 | 38/541 (7) OR = 0.67; 95%CI: 0.48–0.95 1098/7745 (14.2)                                                                 | -                                                                                                                                   |                                                                                              | BMI, sex, age range, diabetes and cardiac failure | 9        |
them showed a significant reduction in the risk of ICU admission and mechanical ventilation among COVID-19 patients with a history of bariatric surgeries. Furthermore, our results showed that COVID-19 patients with a history of bariatric surgeries...
surgeries had a significantly lower risk of COVID-19 mortality by 50%. This finding was consistent across all the studies but only one reached the significance level.

Previous studies showed that obesity is associated with poor COVID-19 outcomes [7] and it’s well established that bariatric surgeries are very effective in weight reduction. Moreover, bariatric surgeries improve several comorbidities including but not limited to hypertension, cardiovascular diseases [8], and diabetes [9], and all of these factors had been correlated to COVID-19 adverse outcomes [3]. This suggests that the benefits of bariatric surgery on COVID-19 outcomes are due to the improvement in one of the aforementioned comorbidities or a combination of all of them.

Since our meta-analysis included a large number of COVID-19 patients, who underwent bariatric surgeries, from three studies and all of them were adjusted extensively for multiple potential confounding factors, the findings can be considered reliable. Our findings suggest a reduction in COVID-19 mortality and severity among patients with a history of bariatric surgeries. This supports the evidence that obesity is a very important risk factor among COVID-19 patients. Also, this substantiates the benefits of bariatric surgeries in improving the outcomes of several diseases. However, much is left to be determined about which type of surgery is more effective and how much time is needed to get the beneficial effects of bariatric surgeries. We await more data from well-designed prospective studies to support our results.

Declarations

Ethical Approval  This article does not contain any studies with human participants or animals performed by any of the authors.

Informed Consent  Not applicable.

Conflict of Interest  The author declares no competing interests.

References

1. le Roux CW, Heneghan HM. Bariatric surgery for obesity. Med Clin N Am. 2018;102(1):165–82. https://doi.org/10.1016/j.mcna.2017.08.011.

2. Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020;28(7):1195–9. https://doi.org/10.1002/oby.22831.

3. Yang J, Hu J, Zhu C. Obesity aggravates COVID-19; a systematic review and meta-analysis. J Med Virol. 2021;93(1):257–61. https://doi.org/10.1002/jmv.26237.

4. Aminian A, Fathalizadeh A, Tu C, et al. Association of prior metabolic and bariatric surgery with severity of coronavirus disease 2019 (COVID-19) in patients with obesity. Surg Obes Relat Dis. 2021;17(1):208–14. https://doi.org/10.1016/j.soard.2020.10.026.

5. Jenkins M, Maranga G, Wood GC, et al. Prior bariatric surgery in COVID-19 positive patients may be protective. medRxiv. 2021:2020.12.29.20248991. https://doi.org/10.1101/2020.12.29.20248991.

6. Iannelli A, Bouam S, Schneck A-S, et al. The impact of previous history of bariatric surgery on outcome of COVID-19. A nationwide medico-administrative French study. Obes Surg. 2021;31(4):1455–63. https://doi.org/10.1007/s11695-020-05120-z.

7. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. https://doi.org/10.1136/bmj.m1985.

8. Ikramuddin S, Komer J, Lee W-J, et al. Lifestyle intervention and medical management with vs without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the diabetes surgery study. JAMA. 2018;319(3):266–78. https://doi.org/10.1001/jama.2017.20813.

9. Douros JD, Tong J, D’Alessio DA. The effects of bariatric surgery on islet function, insulin secretion, and glucose control. Endocrine Reviews. 2019;40(5):1394–423. https://doi.org/10.1210/er.2018-00183.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.